Clinical Hematology Research Career Development Award

申请者描述(申请人提供)：本次“哈佛血液学者”职业发展奖申请旨在延续哈佛医学院附属医院血液学培训项目联盟在非恶性血液学和输血医学领域的K12职业发展计划。这一计划的主要理论基础是需要扭转血液学/肿瘤学奖学金项目毕业生远离良性血液学实践和研究的长期趋势。该计划的第一个周期始于2006年。来自三个成员医院项目的六名学者在NHLBI支持的头五年注册，涉及该项目定义的不同血液学领域，包括骨髓增殖性疾病和骨髓增生异常综合征，细胞治疗(包括基因治疗)和输血医学，以及非恶性血液学的传统学科，包括血栓形成和止血，凝血，贫血，骨髓衰竭，中性粒细胞疾病，铁相关疾病，以及与这些疾病相关的健康服务研究。项目主任Ellis Neufeld博士是一名儿科血液学家和遗传学家，参与了ITP、铁超载和出血性疾病的临床试验，以及遗传性血液疾病的实验室遗传学研究。一个代表这些机构和广泛研究兴趣的咨询委员会作为招生委员会，监督该项目的活动。K12血液学者的主要候选者包括儿童和成人血液学、血液学/肿瘤学和输血医学研究员和讲师，不仅来自我们组成医院的几个培训项目，还包括来自全国各地具有类似级别和兴趣的初级医生-科学家。大多数学者将继续两年的职业发展计划。在某些情况下，可能会提供第三年的支持。该计划的主要组成部分包括(A)以患者为中心的研究方法的正式培训，例如哈佛医学区临床科学、临床有效性或流行病学和转化研究的三个硕士计划，以及一个有指导的研究项目。血液学者系列研讨会每月召开一次，为整个哈佛血液学社区提供以患者为中心的研究讲座。每个学者与他/她的导师和咨询委员会一起制定一个个性化的课程计划，其中考虑到学者的培训水平、背景和对最佳职业发展的需求。该计划的关键短期指标是申请者和入学学者的人口统计数据，以及(A)申请和(B)获得血液学研究高级培训补助金的毕业生比例，特别是K23或K08补助金。从长远来看，毕业生的职业选择和学业成就将是至关重要的。

DESCRIPTION (provided by applicant): This "Harvard Blood Scholars" Career Development Award application is aimed as a renewal of the K12 Career Development Program in non-malignant hematology and transfusion medicine among a consortium of hematology training programs at Harvard Medical School-affiliated hospitals. The key rationale for this program is the need to reverse a long-term trend of graduates of hematology/oncology fellowship programs away from benign hematology practice and research. The first cycle of the program began in 2006. Six scholars, from three of the member hospital programs, matriculated in the first five years of NHLBI support, in diverse areas of hematology as defined for the program, to include myeloproliferative disorders and myelodysplastic syndrome, cell therapy (including gene therapy) and transfusion medicine, and traditional disciplines of non-malignant hematology including thrombosis and hemostasis, coagulation, anemias, marrow failure, disorders of neutrophils, iron-related diseases, and health-services research relating to these disorders. The program director, Dr. Ellis Neufeld, is a pediatric hematologist and geneticist involved in clinica trials of ITP, iron overload, and bleeding disorders, as well as lab-based genetic studies of inherited blood disorders. An advisory committee representing the institutions and broad variety of research interests serves as admissions committee and oversees the activities of the program. The prime candidate pool for K12 Blood Scholars includes pediatric and adult hematology, hematology/oncology and transfusion medicine fellows and instructors not only from the several training programs of our constituent hospitals, but also from junior physician-scientists of similar rank and interests from around the country. Most scholars will pursue two year career development programs. A third year of support may be available in some cases. Key components of the program include (a) formal training in methodology for patient oriented research, exemplified by the Harvard Medical Area's three Masters programs in Clinical Sciences, Clinical Effectiveness or Epidemiology, and Translational Research, and a mentored research project. A Blood Scholars Colloquium Series meets monthly, providing the entire Harvard Hematology community with cutting-edge research talks on patient- oriented studies in the disciplines of the grant. Each scholar develops with his/her mentors and the Advisory Committee an Individualized Curriculum Plan that takes into account the training level, background, and needs of the scholar for optimum career development. The key short-term metrics of the program are the demographics of the applicant and matriculating scholars, and the fraction of graduates who (a) apply for, and (b) receive advanced training grants in hematologic research particularly K23 or K08 grants. In the long run, the career choices and academic success of the graduates will be of paramount importance.